Dissolve Strips ™ Now Available to Aurora's
Canadian Medical Patients
NYSE | TSX: ACB OTC: CTTH
EDMONTON and HAMILTON, ON, Oct. 8,
2019 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora") (NYSE |
TSX: ACB), the Canadian company defining the future of cannabis
worldwide, and CTT Pharmaceutical Holdings, Inc., ("CTT") (OTC |
CTTH) announced today the successful commercialization of CTT's
cannabinoid-infused sublingual wafers. The new cannabis product
line, a first of its kind, has been launched by Aurora in the
Canadian medical cannabis market under the brand name "Dissolve
Strips™".
Aurora has an ownership interest in CTT of approximately 9%,
with a warrant allowing it to increase its stake to 42.5%, and
access to CTT's sublingual wafers drug delivery technology, which
is patent protected or patent pending in multiple
jurisdictions.
"Aurora's Dissolve Strips™ provide unique
advantages over other ingestible products due to their ease of
administration, discrete nature and accurate dosage, that provides
more rapid bioavailability of cannabinoids via sublingual use,"
said Terry Booth, CEO of Aurora.
"This adds yet another innovative offering to our growing portfolio
of high quality, medical products that we offer our patient base,
and is testament to our industry leading ability to work with
technology partners and regulators to bring new form factors to
market rapidly."
CTT's CEO Cam Birge, added, "The
product launch with Aurora of the Dissolve Strips™ is a
major milestone for us that marks the transition of CTT from a
technology development phase to a revenue generating phase. This is
the culmination of years of hard work by our founder Dr. Modi and
the entire CTT and Aurora product development teams. We are very
proud of this co-achievement and congratulate Aurora for the
considerable efforts and product enhancements to bring Dissolve
Strips™ to the cannabis market. Our sights, however, are set
much higher. The next stage in our development will be the launch
of a broader portfolio of unique products on a global scale. We
have been working towards this, and I look forward to reporting on
our progress in the coming quarters."
Orally Dissolvable Thin Film ("ODF") Wafers ("wafers" or
"sublinguals") are a proprietary drug delivery mechanism in the
form of paper-thin polymer films used as carriers for
pharmaceutical agents that have the following benefits:
- ODF Wafer is taken orally but does not require water or
swallowing
- ODF Wafers dissolve quickly in the oral cavity (5-15 seconds),
with the active ingredient rapidly absorbed and diffused for direct
access to the bloodstream.
- The active ingredient, once absorbed, can bypass the liver's
first-pass effect, improving therapeutic outcomes and efficacy
through improved bioavailability, and facilitates excellent patient
compliance.
- ODF Wafers are suitable for a wide range of patients, including
geriatric and pediatric patients who experience difficulty
swallowing.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 25 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Designed to be replicable and
scalable globally, our production facilities are designed to
produce cannabis at significant scale, with high quality,
industry-leading yields, and low-per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern
Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia,
HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs,
Whistler, Chemi Pharmaceutical, and Hempco – Aurora is
distinguished by its reputation as a partner and employer of choice
in the global cannabis sector, having invested in and established
strategic partnerships with a range of leading innovators,
including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd.
(ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH),
Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave
Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group
(private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and is a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
About CTT Pharmaceutical
CTT's principal asset is a unique and novel patented drug
delivery technology, an orally administered, fast dissolving thin
film (the "Wafer"). This technology platform will target both the
human and veterinarian (pet) markets for treatment of many
diseases. The Company believes that its Wafer technology will be
one of the first to gain use in major markets such as pain
management. Several Canadian and U.S. patents protect the Oral Thin
Film (Wafer) formulation.
CTT's oral fast dissolving drug delivery systems consist of
edible Wafers that dissolve without water and within a few seconds
after placement in the mouth. The majority of drugs administered
using our drug delivery system mirror injections in that they have
the ability to enter the bloodstream quickly, are convenient and
discreet, and can be administered anywhere. A faster absorption
rate is achieved because the mouth contains a very thin mucosa and
is extremely vascular. There is no bitter taste, no smoke
inhalation, less degradation of medication (by bypassing the
stomach) and most importantly lower dosage units are required given
the efficacy of absorption. Patient compliance is also improved
especially with those who have a fear of choking or difficulty
swallowing, and/or are pediatric, geriatric or incapacitated.
For more information, please visit our website:
www.cttpharmaceuticals.com
Terry Booth,
CEO
|
Cam Birge,
CEO
|
Aurora Cannabis
Inc.
|
CTT Pharmaceutical
Holdings Inc.
|
Forward Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These statements are only predictions.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-and-ctt-pharmaceutical-announce-launch-of-sublingual-cannabis-wafers-300933570.html
SOURCE Aurora Cannabis Inc.